Reduced expression of MHC class I antigen in human cancer cell lines with defective LMP-7

Anticancer Research

Volumn 20, Issue 2 A, 2000, Pages 949-953

  Yoon, Seong Jun ^a   Kang, Jung Ok ^a   Park, Ji Sung ^a   Kim, Noe Kyeong ^b   Heo, Dae Seog ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

ABC transporters; Cultured tumor cells; Major histocampatibility antigens class I; Neoplasms

Indexed keywords

CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; FLUORESCENCE; GENE DISRUPTION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ATP-BINDING CASSETTE TRANSPORTERS; CYSTEINE ENDOPEPTIDASES; FEMALE; GENES, MHC CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS I; HL-60 CELLS; HUMANS; K562 CELLS; LYMPHOCYTES; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MULTIENZYME COMPLEXES; NEOPLASMS; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; U937 CELLS;

EID: 0034056103     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rammensee HG, Falk K, Rotzschke O: Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 11: 213-244, 1993.
2. Elliot BE, Carlow DA, Rodrick A, Wade A: Perspectives on the role of MHC antigens in normal and malignant cell development. Adv Cancer Res 53: 181-245, 1989.
3. Doyle A, Martin WJ, Funa K, Gazdar A, Carney D, Martin SE, Linnoila I, Cuttitta F, Mulshine J, Bunn P, Minna J: Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med 161: 1135-1151, 1985.
4. Lassam N, Jay G: Suppression of MHC class 1 RNA in highly oncogenic cells occurs at the level of transcription initiation. J Immunol 143: 3792-3797, 1989.
5. Weber JS, Jay G, Tanaka K, Rosenberg SA: Immunotherapy of a murine tumor with interleukin 2: increased sensitivity after MHC class I gene transfection. J Exp Med 166: 1716-1733, 1987.
6. Tanaka K, Isselbacher KJ, Khoury G, Jay G: Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 228: 26-30, 1985.
7. Weis JH, Seidman JG: The expression of major histocompatibility antigens under metallothionein gene promoter control. J Immunol 134: 1999-2003, 1985.
8. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang U, Goldberg AL: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771, 1994.
9. Fehling HJ, Swat W, Laplace C, Kuhn R, Rajewsky K, Muller U, von Boehmer H: MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 265: 1234-1237, 1994.
10. Brown MC, Driscoll J, Monaco JJ: Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes. Nature 353: 355-357, 1991.
11. Glynne R, Powis SH, Bech S, Kelly A, Kerr LA, Trowsdale JA: Proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC. Nature 353: 357-360, 1991.
12. Monaco JJ, Cho S, Attaya M: Transport protein genes in the murine MHC: possible implications for antigen processing. Nature 250: 1723-1726, 1990.
13. Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A: Sequence encoded in the class II region of the MHC related to the 'ABC' superfamily of transporter. Nature 348: 741-744, 1990.
14. Bahram S, Arnold D, Bresnahan M, Strominger JL, Spies T: Two putative subunits of a peptide pump encoded in the human major histocompatibility complex class II region. Proc Nutl Acad Sci USA 88: 10094-10098, 1991.
15. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennick JR: Identification of human cancers deficient in antigen processing. J Exp Med 177: 265-272, 1993.
16. Straten PT, Kirkin AF, Seremet T, Zeuthen J: Expression of transporter associated with antigen processing 1 and 2 (TAP-1/2) in malignant melanoma cell lines. Int J Cancer 70: 582-586, 1997.
17. Trinchieri G: Biology of natural killer cells. Adv Immunol 47: 187-376, 1989.
18. Restifo NP, Mine BR, Taggarse AS, McFarland BJ, Wang M, Irvine KR: Enhancing the recognition of tumor associated antigens. Folia Biol 40: 74-88, 1994.
19. Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, Cameron MJ, Nabel EG, Chang AE: Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci 93: 15388-15393, 1996.
20. Stopeck AT, Hersh EM, Akporiaye ET, Harris DT, Grogan T, Unger E, Warneke J, Schluter SF, Stahl S: Phase I study of direct gene transfer of an allogeneic MHC histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 15: 341-349, 1997.
21. Seliger B, Hohne A, Knuth A, Bernhard H, Ehring B, Tampe R, Huger C: Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinoma with low TAP and LMP expression. Clin Cancer Res 2: 1427-1433, 1996.
22. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR. Identification of human cancers deficient in antigen processing. J Exp Med 177: 265-272, 1996.
23. Cromme FV, Bommel V, Walboomers PF, Gallee MP, Stern PL, Kenemans P, Helmerhorst TJ, Stukart MJ, Meijer CJ: Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumors. Brit J Cancer 69: 1176-1181, 1994.
24. Wright KL, White LC, Kelly A, Beck S, Trowsdale J, Ting JP: Coordinate regulation of the human TAP-1 and LMP-2 genes from a shared bidirectional promoter. J Exp Med 181: 1459-1471, 1995.
25. Singal DP, Ye M, Ni J, Snider DP: Markedly decreased expression of TAP-1 and LMP-2 genes in HLA class I-deficient human tumor cell lines. Immunol Lett 50: 149-154, 1996.